Replimune Group (FRA:7R8) ROCE % : -43.99% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Replimune Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Replimune Group's annualized ROCE % for the quarter that ended in Jun. 2024 was -43.99%.

Replimune Group ROCE % Historical Data

The historical data trend for Replimune Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group ROCE % Chart

Replimune Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-27.90

-20.26

-24.92

-32.63

-39.04

Replimune Group Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															-32.02	-43.29	-38.20	-45.27	-43.99

Replimune Group ROCE % Calculation

Replimune Group's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	-192.028	/	( ( (603.916 - 31.593)	+	(448.704 - 37.203) )	/ 2 )
	=	-192.028	/	( (572.323	+	411.501)	/ 2 )
	=	-192.028	/	491.912
	=	-39.04 %

Replimune Group's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-192.532	/	( ( (448.704 - 37.203)	+	(496.982 - 33.147) )	/ 2 )
	=	-192.532	/	( ( 411.501	+	463.835 )	/ 2 )
	=	-192.532	/	437.668
	=	-43.99 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Replimune Group (FRA:7R8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Replimune Group ROCE % Related Terms

Thank you for viewing the detailed overview of Replimune Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Replimune Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (FRA:7R8) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

REPL:USA

Address

500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801

Website

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group Headlines

No Headlines